Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4667715 | 0.98 | CHRM5 (0.39) | CHRM5ADRA2CHRH3CYP1A2LMNA | |
| SCHEMBL4665976 | 0.93 | CHRM5 (0.34) | CHRM5ADRA2CHRH3CYP1A2LMNA | |
| SCHEMBL4666467 | 0.91 | HRH3 (0.50) | CHRM5ADRA2CHRH3CYP1A2ACHE | |
| SCHEMBL4664557 | 0.89 | HRH3 (0.46) | CHRM5ADRA2CHRH3CYP1A2MAPT | |
| SCHEMBL4667679 | 0.84 | HRH3 (0.41) | HRH3ACHE | |
| SCHEMBL4664110 | 0.80 | ALDH1A1 (0.43) | CYP1A2ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL4666000 | 0.78 | KDM1A (0.35) | ALDH1A1 | |
| SCHEMBL4378814 | 0.77 | HRH3 (0.51) | CHRM5ADRA2CHRH3CYP1A2LMNA | |
| SCHEMBL4378807 | 0.77 | CHRM5 (0.43) | CHRM5ADRA2CHRH3CYP1A2LMNA | |
| SCHEMBL771690 | 0.77 | DRD2 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | HENNEQUIN LAURENT FRANCOIS ANDRE | 2008-12-18 | — | — | US | disclosed |
| US-7371765-B2 | Quinoline derivatives having VEGF inhibiting activity | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | disclosed |
| CN-1315822-C | Quinoline derivatives having VEGF inhibiting activity | STRAZENECA AB (SE) | 2007-05-16 | — | — | CN | disclosed |
| US-20060148819-A1 | Chemical compounds | HENNEQUIN LAURENT F A | 2006-07-06 | — | — | US | disclosed |
| CN-1252065-C | Cinnoline compounds | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | CN | disclosed |
| CN-1245402-C | indole derivatives, process for their preparation, pharmaceutical compositions containing them and their use | ASTRAZENECA AB (SE) | 2006-03-15 | — | — | CN | disclosed |
| US-6887874-B2 | Cinnoline compounds | ASTRAZENECA AB (SE) | 2005-05-03 | — | — | US | disclosed |
| CN-1468230-A | Compound (I) | — | 2004-01-14 | — | — | CN | disclosed |
| US-20030212055-A1 | Cinnoline compounds | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
| US-20030207878-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | disclosed |
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | US | disclosed |
| CN-1446214-A | Cinnoline compounds | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | CN | disclosed |
| CN-1446212-A | Quinoline derivatives having VEGF inhibiting activity | STRAZENECA AB (SE) | 2003-10-01 | — | — | CN | disclosed |
| EP-1313726-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| EP-1311500-A2 | INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-21 | — | — | EP | disclosed |
| EP-1309587-A1 | CINNOLINE COMPOUNDS | AstraZeneca AB (SE) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002016348-A1 | ANTIANGIOGENIC BICYCLIC DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002012227-A2 | INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012228-A1 | CINNOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | VEGFA, FLT1, FLT4 | CHRM5 1292/4885ADRA2C 1602/4885HRH3 27/4885 |
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | VEGFA, FLT1, FLT4 | CHRM5 1885/4885ADRA2C 1149/4885HRH3 145/4885 |
| US-20060148819-A1 | Chemical compounds | VEGFA, NOS3, FLT4 | CHRM5 220/4885ADRA2C 223/4885HRH3 5/4885 |
| US-20030207878-A1 | Chemical compounds | CYP3A7, HTR3C, CNR1 | CHRM5 89/4885ADRA2C 52/4885HRH3 44/4885 |
| US-20030212055-A1 | Cinnoline compounds | VEGFA, PGF, CCR7 | CHRM5 757/4885ADRA2C 142/4885HRH3 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.